Registration Open for 2019 New Frontiers in 3D Conference
Exclusive one-day scientific meeting to discuss practical applications of innovative 3D-cell and organ-on-a-chip technologies to be head April 25, 2019, in Cambridge, MA. PDF Version
Schlieren, Switzerland – January 24, 2019 Registration and abstract submission for the 2019 New Frontiers in 3D Cell Technologies symposium opened today via the conference website. Organized by InSphero AG, a 3D cell culture and organ-on-a-chip pioneer, the conference aims to bring together thought-leaders, research scientists, and regulatory experts actively engaged in pharmaceutical drug discovery and preclinical drug safety testing to discuss innovative trends in 3D cell-based assays and real-world implementation challenges. The conference will feature a keynote presentation by Dr. Matthias von Herrath, Vice President and head of the Novo Nordisk Diabetes R&D Center and Professor at the La Jolla Institute for Immunology.
The one-day scientific meeting, to be held April 25, 2019, at the Massachusetts Institute of Technology in Cambridge, Massachusetts, will include sessions on organ-on-a-chip networks, scalable disease modeling platforms, alternatives to animal testing, and predictive drug safety screening, with invited speakers from AstraZeneca, Takeda Pharmaceuticals, and MIT. Additional speakers will be selected from attendee abstracts submitted for podium presentations, with abstracts for consideration due by March 25, 2019. The registration fee, which includes access to a full day of scientific sessions and discussion, as well as a networking reception and meals, is $299, with an early registration discount available to participants who register before March 25.
InSphero Chief Scientific Officer Dr. Patrick Guye, who helped shaped this year’s conference program and has served on scientific advisory committees for similar conferences and working groups that seek to benefit the broader research community, says, “We are witnessing a convergence of new technologies and methodologies that will revolutionize drug discovery. This New Frontiers in 3D conference offers an international forum to explore how we can effectively harness and apply these emerging technologies, while developing best practices that push the bench closer to the bedside.” The program committee is selecting speakers who are at the forefront of their fields to share their experiences working with organ-on-a-chip systems, scalable 3D cell-based assays, and complex in vitro models that more closely replicate the complexity of healthy and diseased human biology. All participants will be encouraged to voice opinions and actively contribute to the discussion.
To register or learn more about the 2019 New Frontiers in 3D conference, visit newfrontiersin3d.com/
For more information about InSphero, visit insphero.com.
Dr. Frank Junker
Chief Business Officer
Phone +41 44 5150490
Dr. Jan Lichtenberg
Chief Executive Officer
Phone +41 44 5150490
InSphero is the pioneer of industrial-grade, 3D-cell-based assay solutions and scaffold-free 3D organ-on-a-chip technology. Through partnerships, InSphero supports pharmaceutical and biotechnology researchers in successful decision-making by accurately rebuilding healthy and diseased human physiology in vitro. The company’s robust, precisely engineered suite of 3D InSight™ human tissue platforms are used by major pharmaceutical companies worldwide to increase efficiency in drug discovery and safety testing. InSphero specializes in solutions for liver toxicology, metabolic diseases (e.g., T1 & T2 diabetes and NAFLD & NASH liver disease), and oncology (with a focus on immuno-oncology and PDX models). The scalable Akura™ technology, which underlies these 3D InSight™ Discovery and Safety Platforms, includes 96- and 384-well plate formats as well as the Akura™ Flow organ-on-a-chip system. Together, InSphero platforms and technologies are designed to drive efficient innovation throughout all phases of drug development.